Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jul 6;2015(7):CD008242.
doi: 10.1002/14651858.CD008242.pub3.

Amitriptyline for neuropathic pain in adults

R Andrew Moore  1 , Sheena Derry, Dominic Aldington, Peter Cole, Philip J Wiffen
Affiliations
Meta-Analysis

Amitriptyline for neuropathic pain in adults

R Andrew Moore et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an updated version of the original Cochrane review published in Issue 12, 2012. That review considered both fibromyalgia and neuropathic pain, but the effects of amitriptyline for fibromyalgia are now dealt with in a separate review.Amitriptyline is a tricyclic antidepressant that is widely used to treat chronic neuropathic pain (pain due to nerve damage). It is recommended as a first line treatment in many guidelines. Neuropathic pain can be treated with antidepressant drugs in doses below those at which the drugs act as antidepressants.

Objectives: To assess the analgesic efficacy of amitriptyline for relief of chronic neuropathic pain, and the adverse events associated with its use in clinical trials.

Search methods: We searched CENTRAL, MEDLINE, and EMBASE to March 2015, together with two clinical trial registries, and the reference lists of retrieved papers, previous systematic reviews, and other reviews; we also used our own hand searched database for older studies.

Selection criteria: We included randomised, double-blind studies of at least four weeks' duration comparing amitriptyline with placebo or another active treatment in chronic neuropathic pain conditions.

Data collection and analysis: We performed analysis using three tiers of evidence. First tier evidence derived from data meeting current best standards and subject to minimal risk of bias (outcome equivalent to substantial pain intensity reduction, intention-to-treat analysis without imputation for dropouts; at least 200 participants in the comparison, 8 to 12 weeks' duration, parallel design), second tier from data that failed to meet one or more of these criteria and were considered at some risk of bias but with adequate numbers in the comparison, and third tier from data involving small numbers of participants that were considered very likely to be biased or used outcomes of limited clinical utility, or both.

Main results: We included 15 studies from the earlier review and two new studies (17 studies, 1342 participants) in seven neuropathic pain conditions. Eight cross-over studies with 302 participants had a median of 36 participants, and nine parallel group studies with 1040 participants had a median of 84 participants. Study quality was modest, though most studies were at high risk of bias due to small size.There was no first-tier or second-tier evidence for amitriptyline in treating any neuropathic pain condition. Only third-tier evidence was available. For only two of seven studies reporting useful efficacy data was amitriptyline significantly better than placebo (very low quality evidence).More participants experienced at least one adverse event; 55% of participants taking amitriptyline and 36% taking placebo. The risk ratio (RR) was 1.5 (95% confidence interval (CI) 1.3 to 1.8) and the number needed to treat for an additional harmful outcome was 5.2 (3.6 to 9.1) (low quality evidence). Serious adverse events were rare. Adverse event and all-cause withdrawals were not different, but were rarely reported (very low quality evidence).

Authors' conclusions: Amitriptyline has been a first-line treatment for neuropathic pain for many years. The fact that there is no supportive unbiased evidence for a beneficial effect is disappointing, but has to be balanced against decades of successful treatment in many people with neuropathic pain. There is no good evidence of a lack of effect; rather our concern should be of overestimation of treatment effect. Amitriptyline should continue to be used as part of the treatment of neuropathic pain, but only a minority of people will achieve satisfactory pain relief. Limited information suggests that failure with one antidepressant does not mean failure with all.

PubMed Disclaimer

Conflict of interest statement

SD has no conflicts relating to this review or any similar product.

PW has no conflicts relating to this review or any similar product.

RAM has no conflicts relating to this review or any similar product.

DA has no conflicts relating to this review or any similar product.

PC has received research support from industry sources at various times but none related to this review.

For transparency SD, PW, and RAM have received research support from charities, government, and industry sources at various times, but none relate to this review. We are funded by the NIHR for work on a series of reviews informing the unmet need of chronic pain and providing the evidence for treatments of pain.

Figures

1
1
Flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Amitriptyline versus placebo, outcome: 1.1 Third‐tier efficacy.
1.1
1.1. Analysis
Comparison 1 Amitriptyline versus placebo, Outcome 1 Third‐tier efficacy.
1.2
1.2. Analysis
Comparison 1 Amitriptyline versus placebo, Outcome 2 At least 1 adverse event.
1.3
1.3. Analysis
Comparison 1 Amitriptyline versus placebo, Outcome 3 All‐cause withdrawal.
1.4
1.4. Analysis
Comparison 1 Amitriptyline versus placebo, Outcome 4 Adverse event withdrawal.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Anon 2000 {published data only}
    1. Anon. A placebo‐controlled trial of pregabalin and amitriptyline for treatment of painful diabetic peripheral neuropathy. Docstoc.com (accessed 1 September 2012) (date of publication unknown). [http://www.docstoc.com/docs/106010487/PFIZER‐INC‐These‐results‐are‐suppl...
Biesbroeck 1995 {published data only}
    1. Biesbroeck R, Bril V, Hollander P, Kabadi U, Schwartz S, Singh SP, et al. A double‐blind comparison of topical capsaicin and oral amitriptyline in painful diabetic neuropathy. Advances in Therapy 1995;12(2):111‐20. - PubMed
Boyle 2012 {published data only}
    1. Boyle J, Eriksson ME, Gribble L, Gouni R, Johnsen S, Coppini DV, et al. Randomized, placebo‐controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35(12):2451‐8. [DOI: 10.2337/dc12-0656] - DOI - PMC - PubMed
Cardenas 2002 {published data only}
    1. Cardenas DD, Warms CA, Turner JA, Marshall H, Brooke MM, Loeser JD. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002;96(3):365‐73. - PubMed
    1. Turner JA, Jensen MP, Warms CA, Cardenas DD. Blinding effectiveness and association of pretreatment expectations with pain improvement in a double‐blind randomized controlled trial. Pain 2002;99(1‐2):91‐9. [DOI: 10.1016/S0304-3959(02)00060-X] - DOI - PubMed
Graff‐Radford 2000 {published data only}
    1. Graff‐Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clinical Journal of Pain 2000;16(3):188‐92. - PubMed
Jose 2007 {published data only}
    1. Jose VM, Bhansali A, Hota D, Pandhi P. Randomized double‐blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabetic Medicine 2007;24(4):377‐83. [DOI: 10.1111/j.1464-5491.2007.02093.x] - DOI - PubMed
Kautio 2008 {published data only}
    1. Kautio AL, Haanpää M, Saarto T, Kalso E. Amitriptyline in the treatment of chemotherapy‐induced neuropathic symptoms. Journal of Pain and Symptom Management 2008;35(1):31‐9. [DOI: 10.1016/j.jpainsymman.2007.02.043] - DOI - PubMed
Leijon 1989 {published data only}
    1. Leijon G, Boivie J. Central post‐stroke pain ‐ a controlled trial of amitriptyline and carbamazepine. Pain 1989;36(1):27‐36. - PubMed
Max 1988 {published data only}
    1. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988;38(9):1427‐32. - PubMed
Max 1992 {published data only}
    1. Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. New England Journal of Medicine 1992;326(19):1250‐6. - PubMed
Mishra 2012 {published data only}
    1. Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double‐blind placebo‐controlled study. American Journal of Hospice and Palliative Care 2012;29(3):177‐82. [DOI: 10.1177/1049909111412539] - DOI - PubMed
Rintala 2007 {published data only}
    1. Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser PG. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Archives of Physical Medicine and Rehabilitation 2007;88(12):1547‐60. [DOI: 10.1016/j.apmr.2007.07.038] - DOI - PubMed
Rowbotham 2005 {published data only}
    1. Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant‐naïve postherpetic neuralgia patients: double‐blind, randomized trial. Journal of Pain 2005;6(11):741‐6. - PubMed
Shlay 1998 {published data only}
    1. Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV‐related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1998;280(18):1590‐5. - PubMed
Vrethem 1997 {published data only}
    1. Vrethem M, Boivie J, Arnqvist H, Holmgren H, Lindström T, Thorell LH. A comparison a amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clinical Journal of Pain 1997;13(4):313‐23. - PubMed
Watson 1992 {published data only}
    1. Watson CP, Chipman M, Reed K, Evans RJ, Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double‐blind, crossover trial. Pain 1992;48(1):29‐36. - PubMed
Watson 1998 {published data only}
    1. Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998;51(4):1166‐71. - PubMed

References to studies excluded from this review

Achar 2010 {published data only}
    1. Achar A, Chatterjee G, Ray TG, Naskar B. Comparative study of clinical efficacy with amitriptyline, pregabalin, and amitriptyline plus pregabalin combination in postherpetic neuralgia. Indian Journal of Dermatology, Venereology and Leprology 2010;76(1):63‐5. - PubMed
Banerjee 2013 {published data only}
    1. Banerjee M, Pal S, Bhattacharya B, Ghosh B, Mondal S, Basu J. A comparative study of efficacy and safety of gabapentin versus amitriptyline as coanalgesics in patients receiving opioid analgesics for neuropathic pain in malignancy. Indian Journal of Pharmacology 2013;45(4):334‐8. [DOI: 10.4103/0253-7613.115000] - DOI - PMC - PubMed
Bansal 2009 {published data only}
    1. Bansal D, Bhansali A, Hota D, Chakrabarti A, Dutta P. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabetic Medicine 2009;26(10):1019‐26. [DOI: 10.1111/j.1464-5491.2009.02806.x] - DOI - PubMed
Bowsher 1997 {published data only}
    1. Bowsher D. The effects of pre‐emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double‐blind, placebo‐controlled trial. Journal of Pain and Symptom Management 1997;13(6):327‐31. - PubMed
Carasso 1979 {published data only}
    1. Carasso RL, Yehuda S, Streifler M. Clomipramine and amitriptyline in the treatment of severe pain. International Journal of Neuroscience 1979;9(3):191‐4. - PubMed
Hampf 1989 {published data only}
    1. Hampf G, Bowsher D, Nurmikko T. Distigmine and amitriptyline in the treatment of chronic pain. Anesthesia Progress 1989;36(2):58‐62. - PMC - PubMed
Kalso 1996 {published data only}
    1. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996;64(2):293‐302. [DOI: 10.1016/0304-3959(95)00138-7] - DOI - PubMed
Kaur 2011 {published data only}
    1. Kaur H, Hota D, Bhansali A, Dutta P, Bansal D, Chakrabarti A. A comparative evaluation of amitriptyline and duloxetine in painful diabetic neuropathy: a randomized, double‐blind, cross‐over clinical trial. Diabetes Care 2011;34(4):818‐22. [DOI: 10.2337/dc10-1793] - DOI - PMC - PubMed
Kautio 2009 {published data only}
    1. Kautio AL, Haanpää M, Leminen A, Kalso E, Kautiainen H, Saarto T. Amitriptyline in the prevention of chemotherapy‐induced neuropathic symptoms. Anticancer Research 2009;29(7):2601‐6. - PubMed
Kieburtz 1998 {published data only}
    1. Kieburtz K, Simpson D, Yiannoutsos C, Max MB, Hall CD, Ellis RJ, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998;51(6):1682‐8. - PubMed
Lampl 2002 {published data only}
    1. Lampl C, Huber G, Adl J, Luthringshausen G, Franz G, Marecek S, et al. Amitriptyline in the prophylaxis of central poststroke pain. Preliminary results of 39 patients in a placebo‐controlled, long‐term study. Stroke 2002;33(12):3030‐2. - PubMed
Max 1987 {published data only}
    1. Max MB, Culnane M, Schafer SC, Gracely RH, Walther DJ, Smoller B, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37(4):589‐96. - PubMed
McQuay 1992 {published data only}
    1. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992;47(8):646‐52. - PubMed
McQuay 1993 {published data only}
    1. McQuay HJ, Carroll D, Glynn CJ. Dose‐response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993;48(3):281‐5. - PubMed
Mendel 1986 {published data only}
    1. Mendel CM, Klein RF, Chappell DA, Dere WH, Gertz BJ, Karam JH, et al. A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy. JAMA 1986;255(5):637‐9. - PubMed
Mercadante 2002 {published data only}
    1. Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in neuropathic cancer pain in patients on morphine therapy: a randomized placebo‐controlled, double‐blind crossover study. Tumori 2002;88(3):239‐42. - PubMed
Morello 1999 {published data only}
    1. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double‐blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Archives of Internal Medicine 1999;159(16):1931‐7. - PubMed
Pilowsky 1982 {published data only}
    1. Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982;14(2):169‐79. - PubMed
Pilowsky 1990 {published data only}
    1. Pilowsky I, Barrow CG. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990;40(1):3‐19. - PubMed
Robinson 2004 {published data only}
    1. Robinson LR, Czerniecki JM, Ehde DM, Edwards WT, Judish DA, Goldberg ML, et al. Trial of amitriptyline for relief of pain in amputees: results of a randomized controlled study. Archives of Physical Medicine and Rehabilitation 2004;85(1):1‐6. [DOI: 10.1016/S0003-9993(03)00476-3] - DOI - PubMed
Sharav 1987 {published data only}
    1. Sharav Y, Singer E, Schmidt E, Dionne RA, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. Pain 1987;31(2):199‐209. - PubMed
Turkington 1980 {published data only}
    1. Turkington RW. Depression masquerading as diabetic neuropathy. JAMA 1980;243(11):1147‐50. - PubMed
Vanelderen 2015 {published data only}
    1. Vanelderen P, Zundert J, Kozicz T, Puylaert M, Vooght P, Mestrum R, et al. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo‐controlled, double‐blind clinical trial with amitriptyline as a comparator. Anesthesiology 2015;122(2):399‐406. [DOI: 10.1097/ALN.0000000000000508] - DOI - PubMed
Ventafridda 1987 {published data only}
    1. Ventafridda V, Bonezzi C, Caraceni A, Conno F, Guarise G, Ramella G, et al. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. Italian Journal of Neurological Sciences 1987;8(6):579‐87. - PubMed
    1. Ventafridda V, Caraceni A, Saita L, Bonezzi C, Conno F, Guarise G. Trazodone for deafferentation pain. Comparison with amitriptyline. Psychopharmacology (Berl) 1988;95 Suppl:S44‐9. - PubMed
Watson 1982 {published data only}
    1. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32(6):671‐3. - PubMed
Wilder‐Smith 2005 {published data only}
    1. Wilder‐Smith CH, Hill LT, Laurent S. Postamputation pain and sensory changes in treatment‐naive patients: characteristics and responses to treatment with tramadol, amitriptyline, and placebo. Anesthesiology 2005;103(3):619‐28. - PubMed
Zitman 1990 {published data only}
    1. Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. Pain 1990;42(1):35‐42. - PubMed

References to studies awaiting assessment

Keskinbora 2006 {published data only}
    1. Keskinbora K, Pekel AF, Aydinli I. Comparison of efficacy of gabapentin and amitriptyline in the management of peripheral neuropathic pain. Agri (Algoloji) Dernegi'nin Yayin organidir 2006;18(2):34‐40. - PubMed

Additional references

Attal 2010
    1. Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. European Journal of Neurology 2010;17(9):1113‐e88. [DOI: 10.1111/j.1468-1331.2010.02999.x] - DOI - PubMed
Baron 2010
    1. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurology 2010;9(8):807‐19. [DOI: 10.1016/S1474-4422(10)70143-5] - DOI - PubMed
Baron 2012
    1. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19‐21. [DOI: 10.1016/S1474-4422(11)70281-] - DOI - PubMed
Bouhassira 2008
    1. Bouhassira D, Lantéri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] - DOI - PubMed
Bril 2011
    1. Bril V, England J, Franklin GM, Backonja M, Cohen J, Toro D, et al. Evidence‐based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM&R 2011;3(4):345‐52.e21. [DOI: 10.1016/j.pmrj.2011.03.008] - DOI - PubMed
Collins 2000
    1. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. Journal of Pain and Symptom Management 2000;20(6):449‐58. - PubMed
Dechartres 2013
    1. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta‐epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304] - DOI - PMC - PubMed
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Derry 2014
    1. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2] - DOI - PMC - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
Finnerup 2005
    1. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;5(3):289‐305. [DOI: 10.1016/j.pain.2005.08.013] - DOI - PubMed
Finnerup 2015
    1. Finnerup NB, Attal, N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology 2015;14(2):162‐73. [DOI: 10.1016/S1474-4422(14)70251-0] - DOI - PMC - PubMed
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26] - DOI - PMC - PubMed
Hall 2013
    1. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28] - DOI - PMC - PubMed
Hempenstall 2005
    1. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Medicine 2005;2(7):e164. [DOI: 10.1371/journal.pmed.0020164] - DOI - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoffman 2010
    1. Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy?. Pain 2010;149(2):194‐201. [DOI: 10.1016/j.pain.2009.09.017] - DOI - PubMed
Jadad 1996a
    1. Jadad AR, Carroll D, Moore RA, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2‐3):239‐46. - PubMed
Jadad 1996b
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: ] - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011;152(10):2204‐5. [DOI: 10.1016/j.pain.2011.06.017] - DOI - PubMed
Kalso 2013
    1. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339] - DOI - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945‐1984. Neuroepidemiology 1991;10:276‐81. [DOI: 10.1159/000110284] - DOI - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] - DOI - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107:224‐33. - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore R. An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0‐19‐263048‐2]
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic pain. In: Stevens A, Raferty J, Mant J, Simpson S editor(s). Health Care Needs Assessment. Oxford: Radcliffe Publishing Ltd, 2007:519‐600. [ISBN: 978‐1‐84619‐063‐6]
Moisset 2007
    1. Moisset X, Bouhassira D. Brain imaging of neuropathic pain. Neuroimaging 2007;37(Suppl 1):S80‐8. [DOI: 10.1016/j.neuroimage.2007.03.054] - DOI - PubMed
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978–0–931092–69–5]
Moore 2009
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076] - DOI - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2010c
    1. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173‐6. [DOI: 10.1016/j.pain.2009.08.007] - DOI - PubMed
Moore 2010d
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2011a
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: ] - PubMed
Moore 2011b
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012b
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.00] - DOI - PubMed
Moore 2013a
    1. Moore RA, Straube S, Aldington D. Pain measures and cut‐offs ‐ 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400‐12. [DOI: 10.1111/anae.12148] - DOI - PubMed
Moore 2013b
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690] - DOI - PubMed
Moore 2014a
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79‐94. [DOI: 10.1111/papr.12050] - DOI - PubMed
Moore 2014b
    1. Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3] - DOI - PMC - PubMed
Moore 2014c
    1. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions ‐ individual patient data responder analysis. European Journal of Pain 2014;18(1):67‐75. [DOI: 10.1002/j.1532-2149.2013.00341.x] - DOI - PMC - PubMed
Moore 2015
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for fibromyalgia in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD011824] - DOI - PMC - PubMed
Moulin 2007
    1. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain ‐ consensus statement and guidelines from the Canadian Pain Society. Pain Research and Management 2007;12(1):13‐21. - PMC - PubMed
Moulin 2014
    1. Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society. Pain Research and Management 2014;19(6):328‐35. - PMC - PubMed
NICE 2013
    1. National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 19 October 2014).
Nüesch 2010
    1. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta‐analyses of osteoarthritis trials: meta‐epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515] - DOI - PMC - PubMed
O'Connor 2009
    1. O'Connor, AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine 2009;122(10 Suppl):S22‐32. [DOI: 10.1016/j.amjmed.2009.04.007] - DOI - PubMed
Onghena 1992
    1. Onghena P, Houdenhove B. Antidepressant‐induced analgesia in chronic non‐malignant pain: a meta‐analysis of 39 placebo‐controlled studies. Pain 1992;49:205‐20. - PubMed
PaPaS 2012
    1. PaPaS author and referee guidance. papas.cochrane.org/papas‐documents (accessed 9 March 2015).
PCA 2014
    1. Anonymous. Prescription cost analysis, England 2013. Available at: hscic.gov.uk/catalogue/PUB13887/pres‐cost‐anal‐eng‐2013‐rep.pdf (accessed 9 March 2015). Health and Social Care Information Centre, 2014:100‐1. [ISBN: 978‐1‐78386‐089‐0]
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56:127‐38. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Soni 2013
    1. Soni A, Batra R, Gwilym S, Spector T, Hart D, Arden N, et al. Neuropathic features of joint pain: a community‐based study. Arthritis & Rheumatism 2013;65(7):1942‐9. [DOI: 10.1002/art.37962] - DOI - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] - DOI - PubMed
Tracey 2011
    1. Tracey I. Can neuroimaging studies identify pain endophenotypes in humans?. Nature Reviews Neurology 2011;7(3):173‐81. [DOI: 10.1038/nrneurol.2011.4] - DOI - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. [DOI: 10.1212/01.wnl.0000282763.29778.59] - DOI - PubMed
van Hecke 2014
    1. Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155(4):654‐62. [DOI: 10.1016/j.pain.2013.11.013] - DOI - PubMed
Vo 2009
    1. Vo T, Rice AS, Dworkin RH. Non‐steroidal anti‐inflammatory drugs for neuropathic pain: how do we explain continued widespread use?. Pain 2009;143(3):169‐71. [DOI: 10.1016/j.pain.2009.03.013] - DOI - PubMed
von Hehn 2012
    1. Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638‐52. [DOI: 10.1016/j.neuron.2012.02.008] - DOI - PMC - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140-6736(12)61729-2] - DOI - PMC - PubMed
Wiffen 2013a
    1. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia ‐ an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2] - DOI - PMC - PubMed
Wiffen 2013b
    1. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD006044.pub4] - DOI - PMC - PubMed
Wong 2007
    1. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007;335:87. [DOI: 10.1136/bmj.39213.565972.AE] - DOI - PMC - PubMed

References to other published versions of this review

McQuay 1996
    1. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217‐27. - PubMed
Moore 2012a
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Saarto 2007
    1. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances